Please Note: Delivery will be delayed by a few days due for a scheduled holiday break, 03 Mar 2026 to 07 Mar 2026.
We apologize for any inconvenience and will prioritize your shipment as soon as we return.
We apologize for any inconvenience and will prioritize your shipment as soon as we return.
ACE‑083 – 1 mg (Roledapam)
Core Identifiers
- Name: ACE‑083
- Synonyms: ActRIIB ligand trap, investigational myostatin inhibitor
- CAS Number: 81080-10-6
- Quantity: 1 mg (lyophilised powder)
- Formulation: Recombinant fusion protein
Key Features
- Purity: ≥ 95–98% (HPLC‑verified, depending on supplier)
- Endotoxin: ≤ 5 EU/mg
- Form: Freeze‑dried (lyophilised) protein powder
- Documentation: Certificate of Analysis (COA) supplied with every lot
- Mechanism: Functions as a ligand trap for ActRIIB, binding myostatin and related TGF‑β family proteins to promote muscle growth
Protein Information
- Structure: Recombinant fusion protein designed to sequester ligands of activin receptor type IIB
- Classification: Synthetic biologic for research workflows
• Myostatin inhibition studies
• Muscle wasting and neuromuscular disease models
• Duchenne muscular dystrophy (DMD) research
Storage and Stability
- Long‑term: –20 °C, dry and desiccated
- Short‑term: Stable at 2–8 °C
- Handling Note: Avoid repeated freeze–thaw cycles
Intended Use
- For laboratory research only
- Not for human or veterinary use
- Not approved for diagnostic, therapeutic, or medical applications
- Must be handled using appropriate laboratory safety practices
Why Choose ACE‑083 – 1 mg
- Unique mechanism targeting myostatin and activin pathways
- High purity suitable for sensitive experimental systems
- Full batch traceability with COA included
- Lyophilised for extended stability
| Weight | 20 g |
|---|---|
| Dimensions | 1 × 1 × 3 cm |
